A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Chronic Plaque-type Psoriasis Clinical Trial

Official title:
A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Status Completed

Clinical Trial Summary

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01071252
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	March 2010
Completion date	February 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01828086` - Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis	Phase 1
Completed	`NCT00941031` - AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis	Phase 2
Completed	`NCT04207801` - A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis	Phase 2
Completed	`NCT03553823` - Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab	Phase 2